Skip to main content
Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.51
-0.11 (-0.81%)
Nov 13, 2026, 9:49 AM EST - Market open

Trevi Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
1,9261,6053688611620
Market Cap Growth
30.68%336.04%330.28%-26.01%472.04%-54.55%
Enterprise Value
1,6271,411304-216
Last Close Price
13.6212.524.121.341.930.78

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
6.418.763.701.041.081.18
P/TBV Ratio
6.418.763.701.041.081.18

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.000.010.020.090.86
Net Debt / Equity Ratio
-0.99-1.02-1.07-0.99-1.04-1.29
Net Debt / EBITDA Ratio
4.273.812.082.423.730.68
Net Debt / FCF Ratio
4.854.452.782.563.930.76
Quick Ratio
38.2819.4110.2914.338.992.90
Current Ratio
38.8619.6610.4115.039.152.98
Return on Equity (ROE)
-24.67%-30.23%-52.59%-30.59%-46.82%-153.03%
Return on Assets (ROA)
-17.18%-20.26%-32.15%-19.96%-23.15%-47.42%
Return on Capital Employed (ROCE)
-23.10%-26.90%-51.30%-40.60%-27.30%-126.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-2.96%-2.66%-13.01%-33.97%-25.21%-167.88%
FCF Yield
-3.18%-2.62%-10.40%-37.22%-24.50%-143.18%
Buyback Yield / Dilution
-21.68%-32.14%-2.97%-53.44%-182.56%-26.48%
SEC Filings: 10-K · 10-Q